What did AFT Pharmaceuticals Limited announce?
AFT Pharmaceuticals Limited (NZX: AFT) filed “Maxigesic IV Licensed for Japan” with NZX on 27 September 2026, as an operational update announcement.
From the announcement:“AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that they have entered into an exclusive development, license and supply agreement with MIKASASEIYAKU CO., LTD.”
- Which company?
- AFT Pharmaceuticals Limited (NZX: AFT)
- When was it filed?
- 27 September 2026
- Where is the original?
- NZX announcement
Maxigesic IV Licensed for Japan
AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in
New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com
28
th
September 2026
Maxigesic IV Licensed for Japan
AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that they have entered
into an exclusive development, license and supply agreement with MIKASASEIYAKU
CO., LTD. ("Mikasa") for the development and commercialization of AFT's intravenous
fixed-dose combination analgesic, Maxigesic® IV (also known as Combogesic® IV)
in Japan, the third largest pharma market in the world.
Under the agreement, AFT grants Mikasa an exclusive license to seek marketing
authorization for and commercialize the product throughout Japan. AFT will be
responsible for developing and supplying the product, while Mikasa will lead
regulatory submissions to Japan's Pharmaceuticals and Medical Devices Agency
(PMDA), pursue marketing authorization, and development and commercialization
of the product in the Japanese market.
Maxigesic® IV is a proprietary, non-opioid injectable combination of paracetamol
(1000 mg) and ibuprofen (300 mg) developed by AFT for the management of pain.
The collaboration is intended to make this treatment option available to patients
and healthcare providers in Japan.
Under the agreement, AFT will receive an upfront license fee, development
milestones linked to regulatory submission progress and reimbursement pricing in
Japan, with Royalties earned on commercial sales following launch. AFT will also be
supplying the finished product to Mikasa. AFT was assisted with this licensing
agreement in Japan by Shin Nippon Biomedical Laboratories Ltd (TSE: 2395).
Released for, and on behalf of, AFT Pharmaceuticals Limited by Stuart Houliston,
Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter (OTC), prescription and
2
hospital. Our product portfolio comprises both proprietary and in -licensed products,
and includes patented, branded, and generic drugs. Our business model is to
develop and in -license products for in our markets of Australia, New Zealand,
Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-
license our products to local licensees and distributors to over 125 countries around
the world. For more information about the company, visit our
website www.aftpharm.com.
About MIKASASEIYAKU CO., LTD.
https://www.mikasaseiyaku.co.jp/
Guided by its corporate philosophy, “Contributing to society through the healthcare
industry, with pharmaceuticals at its core,” Mikasa has been engaged since its
founding in the research and development, manufacturing, and marketing of
pharmaceuticals, primarily in the field of orthopaedics. Mikasa will continue to
contribute to people’s health and the realization of a prosperous society through the
provision of pharmaceutical products.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- FPH — Fisher & Paykel Healthcare Corporation Limited: FPH to sell portion of Karaka Road land in Drury to HNZ2026-10-04
“News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) Fisher & Paykel Healthcare to sell portion of Karaka Road land in Drury to Health New Zealand for new hospital Auckland, New Zealand, 5 October 2026 – Fisher & Paykel Healthcare has entered into an a…”
- RUA — Rua Bioscience Limited: Rua Bioscience ASM Presentation and Commentary2026-10-20
“Approximately$1mill raised from recent rights issue Working capital is the immediate constraint — not infrastructure $1m Rights Offer outcome • Funds inventory and working capital ahead of sales, particularly to fulfil the UK agreement. • Supports demand in Australia and Aotea…”
- PEB — Pacific Edge Limited: Bell Potter Healthcare Conference 20262026-11-16
“OUTLOOK: POSITIONED TO UNLOCK VALUE MULTIPLE COMMERCIAL, CLINICAL AND INNOVATION CATALYSTS LONG-TERM VALUE CREATION RESEARCH INNOVATION MEDIUM-TERM VALUE CREATION CLINICAL EVIDENCE GENERATION NEAR-TERM VALUE CREATION COMMERCIAL CATALYSTS •Case-by-case reimbursement for Triage…”